Skip to main content

Advertisement

SpringerLink
Log in

Recent Advances in the Treatment of Opioid Use Disorder

  • Alternative Treatments for Pain Medicine (M Jones, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States’ healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy.

Recent Findings

Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments’ market viability.

Summary

This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ B [Internet]. 2015 May [cited 2020 Aug 26];(35):e593–9. Available from: https://pubmed.ncbi.nlm.nih.gov/25993228/.

  2. Stein C. New concepts in opioid analgesia [Internet]. Vol. 27, Expert opinion on investigational drugs. Taylor and Francis Ltd; 2018 [cited 2020 Aug 26]. p. 765–75. Available from: https://pubmed.ncbi.nlm.nih.gov/30148648/.

  3. CDC: Drug overdose deaths up 4.6% in 2019 | AHA News [Internet]. [cited 2020 Sep 11]. Available from: https://www.aha.org/news/headline/2020-07-16-cdc-drug-overdose-deaths-46-2019.

  4. Hagedorn H, Kenny M, Gordon AJ, Ackland PE, Noorbaloochi S, Yu W, et al. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addict Sci Clin Pract [Internet]. 2018 27 [cited 2020 Aug 26];13(1). Available from: https://pubmed.ncbi.nlm.nih.gov/30545409/.

  5. American Psychological Association (APA). Diagnostic and Statistical Manual of Mental Disorders: Depressive Disorders [Internet]. Diagnostic and Statistical Manual of Mental Disorders,. American Psychiatric Publishing, Inc; 2013 [cited 2020 Sep 11]. 1–48 p. Available from: http://dsm.psychiatryonline.org//content.aspx?bookid=556&sectionid=41101760.

  6. Dydyk AM, Jain NK, Gupta M. Opioid use disorder [Internet]. StatPearls. StatPearls Publishing; 2020 [cited 2020 Sep 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31985959.

  7. Lyden J, Binswanger IA. The United States opioid epidemic [Internet]. Vol. 43, Seminars in Perinatology. W.B. Saunders; 2019 [cited 2020 Sep 2]. p. 123–31. Available from: /pmc/articles/PMC6578581/?report=abstract .

  8. Hurd YL, O’Brien CP. Molecular genetics and new medication strategies for opioid addiction [Internet]. Vol. 175, American Journal of Psychiatry. Am Psychiatric Assoc; 2018 [cited 2020 Aug 30]. p. 935–42. Available from: /pmc/articles/PMC6167195/?report=abstract.

  9. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence [Internet]. Vol. 81, Physiological Reviews. Am Physiol Soc; 2001 [cited 2020 Sep 11]. p. 299–343. Available from: http://physrev.physiology.org.

  10. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. [Internet]. Vol. 1, Science & practice perspectives / a publication of the National Institute on Drug Abuse, National Institutes of Health. National Institute on Drug Abuse; 2002 [cited 2020 Sep 11]. p. 13–20. Available from: /pmc/articles/PMC2851054/?report=abstract.

  11. Wallace MS, Papp A. Opioid withdrawal. In: Challenging cases and complication management in pain medicine [Internet]. Springer International Publishing; 2017 [cited 2020 Sep 12]. p. 15–20. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526012/.

  12. Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. N Engl J Med [Internet]. 2003 1 [cited 2020 Sep 12];348(18):1786–95. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra020617.

  13. Module 5: assessing and addressing opioid use disorder (OUD) [Internet]. [cited 2020 Sep 17]. Available from: https://www.cdc.gov/drugoverdose/training/oud/accessible/index.html.

  14. Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ [Internet]. 2018 Mar 5 [cited 2020 Sep 17];190(9):E247–57. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837873/.

  15. Srivastava A, Kahan M, Nader M. Prise en charge des troubles de consommation d’opioïdes en première ligne: abstinence, méthadone ou buprénorphine-naloxone? [Internet]. Vol. 63, Canadian Family Physician. Coll Fam Physicians Can; 2017 [cited 2020 Sep 14]. p. 200. Available from: /pmc/articles/PMC5349718/?report=abstract.

  16. Kreek MJ, Reed B, Butelman ER. Current status of opioid addiction treatment and related preclinical research. Sci Adv [Internet]. 2019 Oct 2 [cited 2020 Sep 14];5(10). Available from: /pmc/articles/PMC6774730/?report=abstract. Review of current OUD treatment options and future therapies.

  17. Hoffman KA, Ponce Terashima J, McCarty D. Opioid use disorder and treatment: challenges and opportunities [Internet]. Vol. 19, BMC Health Services Research. BioMed Central Ltd.; 2019 [cited 2020 Sep 11]. Available from: /pmc/articles/PMC6876068/?report=abstract.

  18. Salsitz E, Wiegand T. Pharmacotherapy of opioid addiction: “putting a real face on a false demon.” J Med Toxicol [Internet]. 2016 Mar 1 [cited 2020 Sep 14];12(1):58–63. Available from: /pmc/articles/PMC4781801/?report=abstract.

  19. Methadone | SAMHSA [Internet]. [cited 2020 Sep 17]. Available from: https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/methadone.

  20. Schuckit MA. Treatment of opioid-use disorders. Longo DL, editor. N Engl J Med [Internet]. 2016 28 [cited 2020 Aug 29];375(4):357–68. Available from: http://www.nejm.org/doi/10.1056/NEJMra1604339.

  21. Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines [Internet]. Vol. 16, Journal of Managed Care Pharmacy. Acad Managed Care Pharm (AMCP); 2010 [cited 2020 Sep 17]. Available from: https://pubmed.ncbi.nlm.nih.gov/20146550/.

  22. Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain [Internet]. Vol. 10, Pain Research and Management. Hindawi Limited; 2005 [cited 2020 Sep 14]. p. 133–44. Available from: https://pubmed.ncbi.nlm.nih.gov/16175249/.

  23. Justo D, Gal-Oz A, Paran Y, Goldin Y, Zeltser D. Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients [Internet]. Vol. 101, Addiction. Addiction; 2006 [cited 2020 Sep 17]. p. 1333–8. Available from: https://pubmed.ncbi.nlm.nih.gov/16911733/.

  24. Worth S, House K. Opioid use disorder: treatment & recovery. N C Med J [Internet]. 2018 [cited 2020 Sep 14];79(3):185–7. Available from: https://pubmed.ncbi.nlm.nih.gov/29735626/.

  25. Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations [Internet]. Vol. 13, Journal of Addiction Medicine. Lippincott Williams and Wilkins; 2019 [cited 2020 Sep 17]. p. 93–103. Available from: /pmc/articles/PMC7442141/?report=abstract. Review of long-acting buprenorphine injection depot.

  26. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther [Internet]. 1994 [cited 2020 Sep 17];55(5):569–80. Available from: https://pubmed.ncbi.nlm.nih.gov/8181201/.

  27. Shulman M, Wai JM, Nunes E V. Buprenorphine treatment for opioid use disorder: an overview [Internet]. Vol. 33, CNS Drugs. Springer International Publishing; 2019 [cited 2020 Sep 18]. p. 567–80. Available from: /pmc/articles/PMC6585403/?report=abstract.

  28. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? [Internet]. Vol. 70, Drug and Alcohol Dependence. Elsevier Ireland Ltd; 2003 [cited 2020 Sep 17]. Available from: https://pubmed.ncbi.nlm.nih.gov/12738348/.

  29. Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option [Internet]. Vol. 78, Drugs. Springer International Publishing; 2018 [cited 2020 Oct 18]. p. 1211–28. Available from: /pmc/articles/PMC6822392/?report=abstract.

  30. Iitzoe ML, Guarnieri M. New developments in managing opioid addiction: impact of a subdermal buprenorphine implant [Internet]. Vol. 11, Drug Design, Development and Therapy. Dove Medical Press Ltd.; 2017 [cited 2020 Sep 18]. p. 1429–37. Available from: /pmc/articles/PMC5436774/?report=abstract.

  31. Singh D, Saadabadi A. Naltrexone [Updated 2019 Oct 9] [Internet]. StatPearls [Internet]. StatPearls; 2019 [cited 2020 Sep 20]. 1–3 p. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30521232.

  32. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review [Internet]. Vol. 113, Addiction. Blackwell Publishing Ltd; 2018 [cited 2020 Sep 20]. p. 1188–209. Available from: /pmc/articles/PMC5993595/?report=abstract. Review of long-acting injectable naltrexone.

  33. Sudakin D. Naltrexone: not just for opioids anymore. J Med Toxicol [Internet]. 2016 [cited 2020 Sep 20];12(1):71–5. Available from: https://pubmed.ncbi.nlm.nih.gov/26546222/.

  34. Lee JD, Nunes E V., Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet [Internet]. 2018 [cited 2020 Sep 20];391(10118):309–18. Available from: /pmc/articles/PMC5806119/?report=abstract.

  35. Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, et al. Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry [Internet]. 2017 [cited 2020 Sep 20];174(5):459–67. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411308/. Trial showing improved XR-naltrexone with PO naltrexone versus buprenorphine taper.

  36. Adler MW, Brady K, Brigham G, Carroll KM, Clayton RR, Cottler LB, et al. Principles of drug addiction treatment: a research-based guide third edition principles of drug addiction treatment A research-based guide third edition iii ii ii iii Acknowledgments Contents.

  37. Baehr C, Pravetoni M. Vaccines to treat opioid use disorders and to reduce opioid overdoses. Vol. 44, Neuropsychopharmacology. Nature Publishing Group; 2019. p. 217–8.

  38. Skolnick P. The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol [Internet]. 2018 [cited 2020 Aug 19];58(1):143–59. Available from: http://www.annualreviews.org/doi/10.1146/annurev-pharmtox-010617-052534. Overview of opioid epidemic, current treatment, and future treatment.

  39. Raleigh MD, Peterson SJ, Laudenbach M, Baruffaldi F, Carroll FI, Comer SD, et al. Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse. Taffe M, editor. PLoS One [Internet]. 2017 [cited 2020 Sep 20];12(12):e0184876. Available from: https://dx.plos.org/10.1371/journal.pone.0184876.

  40. Bremer PT, Schlosburg JE, Banks ML, Steele FF, Zhou B, Poklis JL, et al. Development of a clinically viable heroin vaccine. J Am Chem Soc [Internet]. 2017 [cited 2020 Sep 20];139(25):8601–11. Available from: /pmc/articles/PMC5612493/?report=abstract. Study of a potential heroin vaccine design that is used as the current benchmark.

  41. Hwang CS, Bremer PT, Wenthur CJ, Ho SO, Chiang S, Ellis B, et al. Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality. Mol Pharm [Internet]. 2018 [cited 2020 Sep 20];15(3):1062–72. Available from: /pmc/articles/PMC5912936/?report=abstract. Study describing further advancements for a stable and effective heroin vaccine.

  42. Xiaoshan T, Junjie Y, Wenqing W, Yunong Z, Jiaping L, Shanshan L, et al. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders. Vol. 25, Drug Discovery Today. Elsevier Ltd; 2020. p. 610–9.

  43. Schwienteck KL, Blake S, Bremer PT, Poklis JL, Townsend EA, Negus SS, et al. Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone. Drug Alcohol Depend. 2019;204:107501 Study demonstrating depot naltrexone more effective than heroin-TT vaccine with decreasing heroin antinociceptive potency.

    Article  CAS  Google Scholar 

  44. Crist RC, Reiner BC, Berrettini WH. A review of opioid addiction genetics [Internet]. Vol. 27, Current Opinion in Psychology. Elsevier B.V.; 2019 [cited 2020 Aug 30]. p. 31–5. Available from: /pmc/articles/PMC6368898/?report=abstract. Identified genes from gene candidate studies and GWAS and potential therapeutic value.

  45. Berrettini W. A brief review of the genetics and pharmacogenetics of opioid use disorders. Dialogues Clin Neurosci [Internet]. 2017 [cited 2020 Sep 20];19(3):229–36. Available from: www.dialogues-cns.org.

  46. Coussens NP, Sitta Sittampalam G, Jonson SG, Hall MD, Gorby HE, Tamiz AP, et al. The opioid crisis and the future of addiction and pain therapeutics. J Pharmacol Exp Ther [Internet]. 2019 [cited 2020 Aug 26];371(2):396–408. Available from: /pmc/articles/PMC6863454/?report=abstract Review of 2-day symposium at NIH with experts in addiction and pain discussing solutions to the opioid epidemic.

  47. Wang SC, Chen YC, Lee CH, Cheng CM. Opioid addiction, genetic susceptibility, and medical treatments: a review [Internet]. Vol. 20, International Journal of Molecular Sciences. MDPI AG; 2019 [cited 2020 Aug 26]. Available from: /pmc/articles/PMC6747085/?report=abstract. Review of addiction physiology, genetic component of OUD, and potential future treatments.

  48. Madariaga-Mazón A, Marmolejo-Valencia AF, Li Y, Toll L, Houghten RA, Martinez-Mayorga K. Mu-opioid receptor biased ligands: a safer and painless discovery of analgesics? [Internet]. Vol. 22, Drug Discovery Today. Elsevier Ltd; 2017 [cited 2020 Sep 2]. p. 1719–29. Available from: /pmc/articles/PMC6620030/?report=abstract. Review of biased agonism mechanism and MOR biased agonist agents.

  49. Raehal KM, Schmid CL, Groer CE, Bohn LM. Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance [Internet]. Vol. 63, Pharmacological Reviews. American Society for Pharmacology and Experimental Therapeutics; 2011 [cited 2020 Sep 27]. p. 1001–19. Available from: /pmc/articles/PMC3186080/?report=abstract.

  50. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science (80- ) [Internet]. 1999 [cited 2020 Sep 27];286(5449):2495–8. Available from: https://pubmed.ncbi.nlm.nih.gov/10617462/.

  51. Váradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V, et al. Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with Mu agonism and delta antagonism, which do not recruit β-arrestin-2. J Med Chem [Internet]. 2016 [cited 2020 Sep 27];59(18):8381–97. Available from: https://pubmed.ncbi.nlm.nih.gov/27556704/.

  52. Ehrlich AT, Kieffer BL, Darcq E. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin Ther Targets [Internet]. 2019 [cited 2020 Sep 2];23(4):315. Available from: /pmc/articles/PMC6497449/?report=abstract.

  53. Prozialeck WC. Update on the pharmacology and legal status of Kratom. J Am Osteopath Assoc. 2016;116(12):802–9.

    Article  Google Scholar 

  54. Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol [Internet]. 2017 1 [cited 2020 Sep 27];31(6):730–9. Available from: https://pubmed.ncbi.nlm.nih.gov/28142305/.

  55. Trevena again asks FDA to approve its experimental opioid pain reliever - Philadelphia Bus J [Internet]. [cited 2020 Sep 27]. Available from: https://www.bizjournals.com/philadelphia/news/2020/02/10/trevena-resubmits-a-new-drug-application-for.html.

  56. Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature [Internet]. 2016 [cited 2020 Sep 27];537(7619):185–90. Available from: https://pubmed.ncbi.nlm.nih.gov/27533032/.

  57. Hill R, Disney A, Conibear A, Sutcliffe K, Dewey W, Husbands S, et al. The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br J Pharmacol [Internet]. 2018 [cited 2020 Sep 27];175(13):2653–61. Available from: https://pubmed.ncbi.nlm.nih.gov/29582414/.

  58. Obeng S, Jali A, Zheng Y, Wang H, Schwienteck KL, Chen C, et al. Characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a novel opioid receptor modulator for opioid use disorder treatment. ACS Chem Neurosci [Internet]. 2019 May 15 [cited 2020 Aug 26];10(5):2518–32. Available from: /pmc/articles/PMC6520168/?report=abstract. Significant animal study about NAN.

  59. Cardoso FC, Lewis RJ. Sodium channels and pain: from toxins to therapies [Internet]. Vol. 175, British Journal of Pharmacology. John Wiley and Sons Inc.; 2018 [cited 2020 Oct 18]. p. 2138–57. Available from: https://pubmed.ncbi.nlm.nih.gov/28749537/.

  60. Hoffmann T, Sharon O, Wittmann J, Carr RW, Vyshnevska A, Col R De, et al. NaV1.7 and pain: contribution of peripheral nerves. Pain [Internet]. 2018[cited 2020 Oct 18];159(3):496–506. Available from: https://pubmed.ncbi.nlm.nih.gov/29194125/.

  61. Shields SD, Deng L, Reese RM, Dourado M, Tao J, Foreman O, et al. Insensitivity to pain upon adult-onset deletion of nav1.7 or its blockade with selective inhibitors. J Neurosci [Internet]. 2018[cited 2020 Oct 18];38(47):10180–201. Available from: https://pubmed.ncbi.nlm.nih.gov/30301756/.

  62. Bourinet E, Altier C, Hildebrand ME, Trang T, Salter MW, Zamponi GW. Calcium-permeable ion channels in pain signaling. Physiol Rev [Internet]. 2014 [cited 2020 Oct 18];94(1):81–140. Available from: https://pubmed.ncbi.nlm.nih.gov/24382884/.

  63. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain [Internet]. Vol. 375, The Lancet. Lancet; 2010 [cited 2020 Oct 18]. p. 1569–77. Available from: https://pubmed.ncbi.nlm.nih.gov/20413151/.

  64. Lee S, Jo S, Talbot S, Zhang HXB, Kotoda M, Andrews NA, et al. Novel charged sodium and calcium channel inhibitor active against neurogenic inflammation. Elife [Internet]. 2019 [cited 2020 Oct 18];8. Available from: https://pubmed.ncbi.nlm.nih.gov/31765298/.

  65. Shan Z, Cai S, Yu J, Zhang Z, Vallecillo TGM, Serafini MJ, et al. Reversal of peripheral neuropathic pain by the small-molecule natural product physalin F via block of CaV2.3 (R-type) and CaV2.2 (N-type) voltage-gated calcium channels. ACS Chem Neurosci [Internet]. 2019 [cited 2020 Oct 18];10(6):2939–55. Available from: https://pubmed.ncbi.nlm.nih.gov/30946560/.

  66. Rosenbaum T, Simon SA. TRPV1 receptors and signal transduction [Internet]. TRP Ion Channel Function in Sensory Transduction and Cellular SignalingCascades. 2007 [cited 2020 Oct 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21204507.

  67. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8 patch [Internet]. Vol. 107, British Journal of Anaesthesia. Oxford University Press; 2011 [cited 2020 Oct 18]. p. 490–502. Available from: https://pubmed.ncbi.nlm.nih.gov/21852280/.

  68. Sapio MR, Neubert JK, Lapaglia DM, Maric D, Keller JM, Raithel SJ, et al. Pain control through selective chemo-axotomy of centrally projecting TRPV1+ sensory neurons. J Clin Invest [Internet]. 201[cited 2020 Oct 18];128(4):1657–70. Available from: /pmc/articles/PMC5873867/?report=abstract.

  69. Wang S Historical review: opiate addiction and opioid receptors [Internet]. Vol. 28, Cell Transplantation. SAGE Publications Ltd; 2019 [cited 2020 Aug 30]. p. 233–8. Available from: /pmc/articles/PMC6425114/?report=abstract.

  70. Vanderah TW. Delta and kappa opioid receptors as suitable drug targets for pain [Internet]. Vol. 26, Clin J Pain. Lippincott Williams and Wilkins; 2010 [cited 2020 Oct 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/20026960/.

  71. Beck TC, Hapstack MA, Beck KR, Dix TA. Therapeutic potential of kappa opioid agonists. Pharmaceuticals [Internet]. 2019 [cited 2020 Oct 18];12(2). Available from: /pmc/articles/PMC6631266/?report=abstract.

  72. Ji J, Lin W, Vrudhula A, Xi J, Yeliseev A, Grothusen JR, et al. Molecular interaction between butorphanol and κ-opioid receptor. Anesth Analg [Internet]. 2020 [cited 2020 Oct 18];131(3):935–42. Available from: https://pubmed.ncbi.nlm.nih.gov/32701545/.

  73. Quirion B, Bergeron F, Blais V, Gendron L. The delta-opioid receptor; a target for the treatment of pain [Internet]. Vol. 13, Front Mol Neurosci. Frontiers Media S.A.; 2020 [cited 2020 Oct 18]. Available from: /pmc/articles/PMC7214757/?report=abstract.

  74. Maguire DR, Gerak LR, Cami-Kobeci G, Husbands SM, France CP, Belli B, et al. OREX-1019: a novel treatment of opioid use disorder and relapse prevention. J Pharmacol Exp Ther [Internet]. 2020 Feb 1 [cited 2020 Aug 26];372(2):205–15. Available from: https://pubmed.ncbi.nlm.nih.gov/31748404/.

  75. Vučkovic S, Srebro D, Vujovic KS, Vučetic Č, Prostran M. Cannabinoids and pain: new insights from old molecules. Front Pharmacol [Internet]. 2018 [cited 2020 Oct 18];9(NOV). Available from: https://pubmed.ncbi.nlm.nih.gov/30542280/.

  76. Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The cholinergic system as a treatment target for opioid use disorder. CNS Drugs [Internet]. 2018[cited 2020 Sep 14];32(11):981–96. Available from: /pmc/articles/PMC6314885/?report=abstract.

  77. Neelakantan H, Holliday ED, Fox RG, Stutz SJ, Comer SD, Haney M, et al. Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. ACS Chem Neurosci [Internet]. 2017 [cited 2020 Sep 28];8(5):1065–73. Available from: https://pubmed.ncbi.nlm.nih.gov/28107783/.

Download references

Author information

Authors and Affiliations

  1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Sumanth Kuppalli & Raghav Seth

  2. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Vwaire Orhurhu

  3. Southcoast Health, Southcoast Health Physicians Group, Fall River, MA, USA

    Ivan Urits

  4. Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA

    Ivan Urits & Alan D. Kaye

  5. Ainsworth Institute of Pain Management, New York, NY, USA

    Corey Hunter

  6. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Amitabh Gulati

  7. Departments of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Peju Adekoya

  8. Thomas J. Long School of Pharmacy and Health Sciences, Department of Pharmacy Practice, University of the Pacific, Stockton, CA, USA

    Adam M. Kaye

  9. Department of Anesthesiology, Weill Cornell Medical College, New York, NY, USA

    Mark R. Jones

Authors
  1. Sumanth Kuppalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raghav Seth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vwaire Orhurhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ivan Urits
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alan D. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Corey Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amitabh Gulati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peju Adekoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Adam M. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mark R. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark R. Jones.

Ethics declarations

Conflict of Interest

Drs. Kuppalli, Seth, Orhurhu, Urits, Hunter, Alan Kaye, Adam Kaye, and Jones have no conflicts of interest. Dr. Gulati is a medical advisor for AIS, a consultant for Medtronic, Flowonix, SPR Therapeutics, Nalu Medical, Bausch Health. Dr. Adekoya has an active educational grant from Medtronics.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Alternative Treatments for Pain Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuppalli, S., Seth, R., Orhurhu, V. et al. Recent Advances in the Treatment of Opioid Use Disorder. Curr Pain Headache Rep 25, 23 (2021). https://doi.org/10.1007/s11916-021-00941-8

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11916-021-00941-8

Keywords

Search

Navigation